Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines
November 04, 2020 09:16 ET
|
Generex Biotechnology Corp.
Framework agreement outlines structure for project contracts: Ii-Key Vaccine for COVID-19Ii-Key Vaccine for Swine FluIi-Key Platform for Cancer and Infectious Diseases Impending contract to establish...
NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website
November 03, 2020 12:00 ET
|
Generex Biotechnology Corp.
https://www.nugenerexio.com/The “Complete Vaccine” for Cancer and Infectious DiseaseIi-Key COVID VaccineAE37 Immunotherapeutic VaccineManagement & Board of DirectorsScientific Advisory Board ...
Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program
October 30, 2020 09:00 ET
|
Generex Biotechnology Corp.
-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of Alabama, Professor of Pediatrics and Internal Medicine, Director of the...
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine
October 13, 2020 09:25 ET
|
Generex Biotechnology Corp.
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design Immunotherapy with cancer vaccines explainedReview of cancer vaccine trials: design, results,...
Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday October 8, 2020 at 8:00 AM
October 07, 2020 15:32 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday...
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets
October 07, 2020 08:53 ET
|
Generex Biotechnology Corp.
Bintai Kinden Corporation Berhad (www.bintai.com.my), an investment holding company headquartered in Malaysia will fund the U.S. Clinical Trials for the Ii-Key-SARS-CoV-2 vaccine against...
Generex Subsidiary NuGenerex Immuno-Oncology Announces World Class Scientific Advisory Board Appointments for its COVID-19 Vaccine Development Program
October 06, 2020 08:30 ET
|
Generex Biotechnology Corp.
Co-Chairs to guide the development of Ii-Key-SARS-CoV-2 Vaccine as a safe & effective vaccine targeted for the pediatric populationDr. Jonathan Davis is Vice-Chair of Pediatrics and Chief of...
NuGenerex Immuno-Oncology Announces Shareholder Conference Call on Thursday October 8, 2020 at 8:00 AM
October 02, 2020 12:48 ET
|
Generex Biotechnology Corp.
Closing of licensing & distribution agreement with Bintai for COVID-19 vaccine in MalaysiaUpdate on Ii-Key-SARS-CoV-2 vaccine development & international licensing opportunitiesCOVID-19...
Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) Services
September 25, 2020 09:00 ET
|
Generex Biotechnology Corp.
- NuGenHealth Software as a Service (SaaS) platform launch- PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population MIRAMAR, Fla., Sept. 25, 2020 ...
Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
September 18, 2020 09:00 ET
|
Generex Biotechnology Corp.
Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf RegionUpfront...